[Methotrexate therapy of polymyalgia rheumatica].
Twenty-seven patients with polymyalgia rheumatica were treated with methotrexate. In comparison with 295 patients with other inflammatory rheumatic diseases under methotrexate therapy, a favorable rate of therapeutic effect and a low rate of side-effects could be observed. Remissions appeared in the mean after 6 months (1-24 months). Therapeutic failures (1/27) or side-effects inducing breaking off the therapy (2/27) were rare. Methotrexate seems to be a useful possibility to supplement the corticosteroid therapy of polymyalgia rheumatica.
Wagener
P
P
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011111:Polymyalgia Rheumatica / Q000188:drug therapy*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D008727:Methotrexate
Methotrexattherapie der Polymyalgia rheumatica.